State-of-the Art in Alzheimer's Research Featured at 25th Conference of Alzheimer's Disease International

LONDON, March 4, 2010 - "What's new" in Alzheimer's disease medical treatments and diagnosis is
the focus of the first day's plenary sessions at the 25th International
Conference of Alzheimer's Disease International (ADI), March 11, 2010 at the
Grand Hotel Palace, Thessaloniki, Greece.

Sam Gandy, M.D., Ph.D. of Mount Sinai Alzheimer's Disease Research
Center, New York, will address "New Treatment Developments" in Alzheimer's,
including therapies that have the greatest potential for entering clinical
practice in the next few years - bapineuzumab, latrepirdine, and gamma
secretase inhibitors. He also will touch on intriguing science that may
explain the link between Alzheimer's and diabetes.

"Neuroimaging Perspectives" is the topic of Prof. Frank Jessen of the
University of Bonn, Germany. The presentation will cover recent advances in
both magnetic resonance imaging (MRI) and positron emission tomography (PET)
in Alzheimer's. In particular, how the two technologies have contributed
substantially to both better diagnosis and understanding the progression of
the disease.

Pieter Jelle Visser, M.D. of Maastricht University Medical Centre and VU
University Medical Centre, Amsterdam, The Netherlands will cover "MCI and the
Early Diagnosis of Alzheimer's Disease." Mild cognitive impairment (MCI)
refers to cognitive impairment not severe enough to meet the criteria of
dementia. Using biomarkers and cognitive testing, it is possible to estimate
the risk that a person with MCI will progress to Alzheimer's. Visser will
provide an overview of markers for Alzheimer's in people with MCI and discuss
how they may prove useful in clinical research, earlier diagnosis and
treatment.

Bengt Winblad, M.D., Ph.D., of the Karolinska Institutet, Stockholm and
Karolinska University, Huddinge, Sweden, will speak on "Ongoing clinical
trials in Alzheimer's disease."

The day's second plenary session will focus on the "Global Alzheimer's
Movement." Other plenaries will focus on treatments without drugs, and best
practices in dementia care. For more information, visit
www.adi2010.org/

ADI is working closely with the Greek Association of Alzheimer's Disease
and Related Disorders in organizing this conference.

Alzheimer's Disease International is an international federation of 71
Alzheimer associations around the world, in official relations with the World
Health Organization. ADI's mission is to improve the quality of life of
people with dementia and their families throughout the world. Please visit
www.alz.co.uk/adi/.

Contacts:

Niles Frantz, Alzheimer's Association (Chicago), +1-312-335-5777,
niles.frantz@alz.org

Marc Wortmann, Alzheimer's Disease International (London),
+44-20-7981-0880, m.wortmann@alz.co.uk

Contacts: Niles Frantz, Alzheimer's Association (Chicago), +1-312-335-5777, niles.frantz at alz.org; Marc Wortmann, Alzheimer's Disease International (London), +44-20-7981-0880, m.wortmann at alz.co.uk